Table 2.
Characteristics of studies included in the meta-analysis
| Study(reference) | Patients | Ways of Presenting Results | Ethnicity(Country) | Evaluationcriteria | Samplesize | Chemotherapeutic regimens | Outcomes |
|---|---|---|---|---|---|---|---|
| Chen et al (2010) | patients with unresectable advancedgastric carcinoma | 677T CT/TT vs CC |
Mixed (TaiwanArgentina, South Korea andMexico) | NR | 65 | pemetrexed + cisplatin | OS |
| Gao et al (2004) | Patients with advanced GC | 677T TT vs CC/CT |
Asian(China) | RECIST | 75 | 5-Fu et al. | RR and toxicity |
| Goekkurt et al (2009) |
Patients with metastatic gastroesophageal adenocarcinoma | 677T TT vs CC/CT |
European(Germany) | RECIST | 134 | fluorouracil+leucovorin+oxaliplatin or fluorouracil+leucovorin+ cisplatin | RR |
| Huang et al (2008) | Patients with GC after curative surgery | 677T CT/TT vs CC |
Asian(China) | NR | 116 | 5-Fu/CF/oxaliplatin 5-Fu/CF/taxanes 5-Fc/CF/oxaliplatin/other regimens |
OS |
| Liu et al (2015) | Patients with metastatic GC | 677T CT/TT vs CC |
Asian(China) | RECIST | 108 | EOF: epirubicin+ oxaliplatin+ 5-Fu | OS |
| Meulendijks1 et al (2016) | Patients with advanced HER2(-) GC | 677T TT vs CC/CT |
European( Netherlands ) | NR | 56 | B-DOC, bevacizumab, docetaxel, oxaliplatin, capecitabine; followed by Maintenance with Capecitabine |
OS and toxicity |
| Meulendijks2 et al (2016) | Patients with advanced GC | 677T TT vs CC/CT |
European( Netherlands ) | NR | 185 | B-DOC, bevacizumab, docetaxel, oxaliplatin, capecitabine;B-DOCT, bevacizumab, docetaxel, oxaliplatin, capecitabine, trastuzumab;DOC, docetaxel, oxaliplatin, capecitabine; ECC, epirubicin, cisplatin, capecitabine; |
OS, RR and toxicity |
| Ott et al (2006) | Neoadjuvant chemotherapy forpatients with locally advanced GC | 677T TT vs CC CT vs CC |
European(Germany) | Others | 135 | 5-Fu+cisplatin | RR and OS |
| Ott et al (2011) | Neoadjuvant chemotherapy forpatients with locally advanced GC | 677T TT vs CC CT vs CC |
European(Germany) | Others | 144 | 5-Fu+leucovorin + cisplatin | OS |
| Roberto et al (2017) | adjuvant chemotherapy forpatients with early stage GC | 677T TT vs CC/CT |
European(Italy) | NR | 142 | capecitabine | toxicity |
| Ruzzo et al (2006) | Patients with advanced GC | 677T TT vs CC/CT |
European(Italy) | Others | 175 | fluorouracil/cisplatin | RR |
| Shitara et al (2010) | Patients with inoperable GC | 677T TT vs CC/CT |
Asian(Japan) | NR | 132 | 5-Fu et al. | OS and toxicity |
| Zhao et al (2016) | stage II-III patients | 677T CT/TT vs CC TT vs CC CT vs CC |
Asian(China) | NR | 251 | 5-Fu et al. | OS |
GC: gastric cancer; Others: evaluation criteria which were described in original papers; NR: not reporting; RR: response rate; OS: overall survival; Meulendijks 1 et al represents article published by this author in the journal Cancer; Meulendijks 2 et al represents article published by this author in the journal Pharmacogenomics.